Death (any cause) · people with CKD who are overweight or obese
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular events · people with CKD who are overweight or obese
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ weight loss · people with CKD who are overweight or obese
1 finding from 1 review
Body‐mass index (BMI) · people with CKD who are overweight or obese
1 finding from 1 review
Waist circumference · people with CKD who are overweight or obese
1 finding from 1 review
Proteinuria · people with CKD who are overweight or obese
1 finding from 1 review
Systolic blood pressure · people with CKD who are overweight or obese
1 finding from 1 review
Symptomatic, culture‐verified UTI People with a susceptibility to a UTI due to an intervention · preventing UTI
Any cranberry product may leads to lower symptomatic, culture‐verified UTI People with a susceptibility to a… compared with placebo or control (low certainty).
1 finding from 1 review
Vertebral fracture by radiography · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs may leads to lower vertebral fracture by radiography compared with placebo (low certainty).
1 finding from 1 review
Clinical fracture · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in clinical fracture compared with placebo (moderate certainty).
1 finding from 1 review
Mean change in BMD of the femoral neck · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Mean change in BMD of the lumbar spine · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Total hip BMD · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Mean change in BMD of the distal radius · postmenopausal women with osteoporosis and CKD stages 3‐4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Death · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
QoL · postmenopausal women with osteoporosis and CKD stages 3‐4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Persistent kidney disease at any time after treatment · patients with IgAV
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 3 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
2 findings from 1 review
Children with any continuing kidney disease at 6 months · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review